Corbett v. PharmaCare U.S., Inc.

CourtDistrict Court, S.D. California
DecidedJuly 20, 2022
Docket3:21-cv-00137
StatusUnknown

This text of Corbett v. PharmaCare U.S., Inc. (Corbett v. PharmaCare U.S., Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Corbett v. PharmaCare U.S., Inc., (S.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 MONTIQUENO CORBETT, DAMARIS Case No.: 21cv137-GPC(AGS) LUCIANO, and ROB DOBBS, 12 individually and on behalf of all others ORDER RE; PLAINTIFFS’ MOTION 13 similarly situated, FOR VOLUNTARY DIMISSAL OF PLAINTIFF DAMARIS LUCIANO 14 Plaintiffs, WITHOUT PREJUDICE 15 v. [Dkt. No. 59.] 16 PHARMACARE U.S., INC., 17 Defendant. 18 19 Before the Court is Plaintiffs’ motion for voluntary dismissal of Plaintiff Damaris 20 Luciano pursuant to Federal Rule of Civil Procedure 41(a)(2). (Dkt. No. 59.) Defendant 21 filed an opposition to which Plaintiffs replied. (Dkt. Nos. 69, 73.) The Court finds that 22 the matter is appropriate for decision without oral argument pursuant to Local Civ. R. 23 7.1(d)(1). Based on the reasoning below, the Court intends to GRANT Plaintiffs’ motion 24 for voluntary dismissal of Plaintiff Damaris Luciano without prejudice on the condition 25 that she responds to discovery requests. 26 BACKGROUND 27 On January 25, 2021, Plaintiffs Montiqueno Corbett (“Corbett”), Damaris Luciano 28 (“Luciano”) and Rob Dobbs (“Dobbs”) (collectively “Plaintiffs”) filed a putative class 1 action complaint against Defendant PharmaCare U.S., Inc. (“Defendant” or 2 “PharmaCare”) for violations of consumer fraud statutes for its sale of Sambucol, a 3 dietary supplement that contains a proprietary extract of black elderberry. (Dkt. No. 1, 4 Compl.) On June 17, 2021, the Court granted in part and denied in part Defendant’s 5 motion to dismiss the complaint. (Dkt. No. 29.) On July 7, 2021, Plaintiffs filed a first 6 amended putative class action complaint (“FAC”). (Dkt. No. 31, FAC.) On October 19, 7 2021, the Court granted in part and denied in part Defendant’s motion to dismiss the 8 FAC. (Dkt. No. 44.) Specifically, the Court granted dismissal of California’s Consumer 9 Legal Remedies Act claim for damages and the cause of action under Mass. Gen. Law ch. 10 93A without prejudice for failing to comply with the notice provisions under both 11 statutes. (Id. at 38.) After curing the deficiencies, the operative second amended putative 12 class action complaint (“SAC”) was filed on November 29, 2021. (Dkt. No. 45.) On 13 December 13, 2021, Defendant filed its answer. (Dkt. No. 47.) 14 The operative SAC alleges seven causes of action based on the alleged misleading 15 labeling, advertising and sale of twelve dietary supplement products (“Products”) under 16 the name Sambucol for violations of 1) California’s Unfair Competition Law (“UCL”) 17 pursuant to California Business & Professions Code section 17200 et seq. on behalf of a 18 national class and the California subclass; 2) California’s False Advertising Law (“FAL”) 19 under California Business & Profession Code section 17500 et seq. on behalf of the 20 California subclass; 3) California’s Consumer Legal Remedies Act (“CLRA”) under 21 California Civil Code section 1750 et seq. on behalf of the California subclass; 4) 22 violations of Massachusetts General Laws Chapter 93A, section 2, Mass. Gen. Laws. Ch. 23 93A, § 2 (“M.G.L. ch. 93A”), on behalf of the Massachusetts subclass; 5) Missouri 24 Merchandising Practices Act (“MMPA”) pursuant to Mo. Ann. Stat. section 407.010 et 25 seq. on behalf of the Missouri subclass; 6) breach of express warranties on behalf of a 26 national class and the subclasses; and 7) breach of the implied warranty of 27 merchantability on behalf of a national class and the subclasses. (Dkt. No. 45, SAC.) 28 Plaintiff Corbett is a resident and citizen of San Diego, California, Plaintiff Luciano is a 1 resident and citizen of Holyoke, Massachusetts, and Plaintiff Dobbs is a resident and 2 citizen of Florissant, Missouri. (Id. ¶¶ 14-16.) They all purchased certain of the Products 3 at issue after being exposed to, saw and relied on Defendant’s materially misleading 4 representations on either the Products’ packaging and labeling, on advertisements on T.V. 5 or on websites. (Id. ¶¶ 80-102.) When they purchased the Products, they believed they 6 were legally sold supplements and they all claim they experienced no improvement in 7 their health after using the Products. (Id. ¶¶ 82, 83, 90, 91, 98, 99.) Plaintiffs seek to 8 certify a national class defined as: “During the fullest period allowed by law, all persons 9 in the United States who purchased the Products (the ‘National Class’) for personal use 10 and not for resale.” (Id. ¶ 103.) They also seek to certify a California, Massachusetts and 11 Missouri subclass. (Id.) 12 A case management order was filed on January 26, 2022. (Dkt. No. 52.) On 13 December 27, 2021, Defendant served the identical discovery requests to all Plaintiffs. 14 (Dkt. No. 69-1, Ferrari Decl. ¶ 21; Dkt. No. 59-2, Soffin Decl. ¶ 2; Dkt. No. 73-1, 15 Kashima Decl. ¶ 2.) Corbett and Dobbs timely responded to the discovery requests and 16 sat for their depositions. (Dkt. No. 59-2, Soffin Decl. ¶ 4.) Despite a two-week 17 extension stipulated by Defendant, Luciano did not provide any discovery responses by 18 the February 9, 2022 deadline and has still not served any discovery responses; in 19 addition, her counsel did not preserve her objections to Defendant’s discovery requests. 20 (Dkt. No. 69-1, Ferrari Decl. ¶ 22.) Defendant made repeated requests for Luciano’s 21 discovery responses. (Id. ¶ 26.) On February 24, 2022 Plaintiffs’ counsel indicated she 22 “will be filing a notice of voluntary dismissal . . . without prejudice.” (Id.) However, 23 because no dismissal was filed, on April 1, 2022, Defendant made a follow-up request. 24 (Id. ¶ 27.) On April 7, 2022, Defendant sought a discovery conference with the 25 Magistrate Judge. (Id. ¶ 28.) 26 On April 11, 2022, the parties filed a joint letter brief on Defendant’s motion to 27 compel Luciano to “(1) appear for a deposition before May 6, 2022; (2) serve, within 7 28 days, verified, written responses, without objections, to PharmaCare’s first set of 1 interrogatories and first set of request for production; and (3) produce, within 10 days, all 2 documents responsive to PharmaCare’s first set of requests for production, without 3 objection. (Dkt. No. 56 at 1.1) Defendant argued that Luciano failed timely to respond or 4 object to PharmaCare’s written discovery despite repeated follow-ups and failed to 5 appear for a noticed deposition, and refuses to commit to any date for her deposition 6 despite repeated follow-ups. (Id.) Even though Plaintiffs’ counsel indicated that Luciano 7 intended to file a voluntary dismissal, no request was ever made so Defendant filed the 8 motion to compel after defense counsel made a final request on April 1, 2022. (Id.) in 9 opposition, Plaintiffs explained that “Luciano has held more than one job at a time to 10 financially care for her family since the inception of this litigation. Her current job 11 working as a nightshift nurse (just one of her jobs), coupled with her parental 12 responsibilities, only allow her to sleep four hours a night during her shifts. This has 13 made it incredibly difficult for her to carry out her responsibilities as a class 14 representative and to timely/regularly communicate with Plaintiffs’ counsel.” (Id. at 2.) 15 “In February 2022, Plaintiffs’ counsel informed Defendant that they had been unable to 16 reach Ms. Luciano. However, in early March 2022, after multiple unproductive attempts 17 to maintain regular contact, Ms. Luciano reemerged and expressed a renewed 18 commitment to this litigation. Following that assurance, Ms. Luciano again became 19 uncommunicative.” (Id.) At the time, Plaintiffs’ counsel contemplated filing a motion to 20 withdraw as counsel. (Id.) On April 8, 2022, Plaintiffs’ counsel was able to speak with 21 Luciano where she agreed to dismiss her individual claims without prejudice so that she 22 could participate as an absent class member. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Corbett v. PharmaCare U.S., Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/corbett-v-pharmacare-us-inc-casd-2022.